1. Singapore Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Haw Par Corporation Limited

Haw Par Corporation Limited

H02.SI
Haw Par Corporation LimitedSG flagStock Exchange of Singapore
16.07
SGD
+0.14
- -
3.56BMarket Cap
Haw Par Corporation Limited
H02.SI
(Stock Exchange of Singapore)

Recent

price

16.07

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.6
0.61
0.64
0.65
0.7
0.82
0.92
1.01
1.08
1.1
0.5
0.64
0.82
1.05
1.11
1.04
1.1
Revenue per Share
0.52
0.37
0.55
0.49
0.54
0.84
0.57
0.56
0.81
0.82
0.54
0.5
0.67
0.98
1.03
1.2
0.82
Basic EPS, GAAP
0.15
0.21
0.38
0.42
0.25
0.56
0.4
0.28
0.3
0.37
0.08
0.07
0.1
0.25
0.23
0.25
0.37
Free Cash Flow per Basic Share
0.18
0.18
0.18
0.19
0.2
0.2
0.39
0.2
0.25
1.15
0.3
0.3
0.3
0.35
0.4
1.4
1.15
Dividend per Share
1.11
1.11
4.54
4.85
5.19
5.84
5.28
5.75
6.52
6.21
6.52
6.72
7.09
7.72
8.35
8.15
6.22
Book Value per Share
8.96
8.16
10.29
11.14
12.78
11.52
10.55
13.95
13.22
14.23
13
14.46
15.98
15.65
18.69
19.33
14.23
Tangible Book Value per Share
217
218
218
219
219
219
219
220
221
221
221
221
221
221
221
221
221
Basic Weighted Avg Shares
130
133
139
141
154
179
202
223
238
244
111
141
182
232
245
230
244
Sales/Revenue/Turnover
26.64
23.71
22.87
26.49
27.87
29.79
35.75
32.18
35.01
32.35
12.55
17.49
23.82
27.58
26.08
29.17
32.35
Operating Margin (%)
5
6
5
5
5
5
3
6
6
6
7
6
6
6
6
6
6
Depreciation Expense
113
80
120
108
119
183
125
122
179
182
120
110
148
217
228
265
182
Net Income, GAAP
8.88
7.21
5.78
6.38
6.41
5.36
9.95
11.16
6.87
7.49
3.57
5.23
6.7
5.59
7.25
5.75
7.49
Effective Tax Rate (%)
86.7
60.15
86.09
76.44
77.05
102.48
62.01
54.97
75.3
74.68
107.87
77.99
81.45
93.32
93.24
115.43
74.68
Profit Margin (%)
435
370
481
572
621
631
2,276
3,046
2,826
3,063
2,775
3,100
3,153
3,190
3,915
4,165
3,063
Working Capital
- -
- -
- -
- -
- -
- -
46
45
- -
9
1
1
29
28
- -
45
9
LT Debt
1,960
1,789
2,253
2,445
2,807
2,535
2,325
3,078
2,928
3,156
2,885
3,211
3,549
3,476
4,149
4,291
3,156
Total Equity
1.62
1.55
1.47
1.47
1.5
1.85
2.59
2.27
2.52
2.37
0.44
0.77
1.19
1.7
1.54
1.47
2.37
Return on Invested Capital (%)
45.28
31.58
18.99
10.33
10.48
14.6
9.74
9.43
12.73
12.78
8.46
7.51
9.64
13.07
12.72
14.13
12.78
Return on Capital (%)
46.79
33.01
19.5
10.54
10.83
15.17
10.26
10.11
13.24
12.95
8.51
7.52
9.7
13.21
12.84
14.54
12.95
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'19
Sep'19
Dec'19
ST Debt
24
24
9
LT Borrowings
24
24
8
LT Finance Leases
- -
- -
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
221
221
221
Market Capitalization
2,636
2,956
2,826

Working Capital

FRC

•

in mil. unless spec.
Jun'19
Sep'19
Dec'19
Total Current Assets
3,045
3,030
3,138
Cash, Cash Equivalents & STI
2,975
2,969
3,087
Accounts Receivable, Net
49
41
24
Inventories
22
19
20
Total Current Liabilities
102
102
75
Payables & Accruals
- -
- -
- -
ST Debt
24
24
9
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.1%
8.51%
3.44%
Free Cash Flow
8.3%
37.85%
9.3%
Net Income, GAAP
7.42%
18.87%
16.29%
Sales/Revenue/Turnover
6.11%
16.6%
-6.07%
Total Cash Common Dividend
63.98%
56.21%
250%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
232
2024
- -
- -
- -
- -
245
2025
- -
- -
- -
- -
230

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.98
2024
- -
- -
- -
- -
1.03
2025
- -
- -
- -
- -
1.2

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.35
2024
- -
- -
- -
- -
0.4
2025
- -
- -
- -
- -
1.4
Similar Companies
BCWORLD PHARM. Co., Ltd. (200780.KQ)
GlaxoSmithKline plc (GSK.SW)
AstraZeneca PLC (AZN.L)
Roche Holding AG (RHHVF)
Vectura Group plc (VEC.L)
Shangya Technology Co., Ltd. (6130.TWO)
Business
Haw Par Corporation Limited is a Singapore-based conglomerate primarily engaged in the manufacture and sale of healthcare products, leisure and property investment. Its core business includes consumer healthcare products such as Tiger Balm ointments and plasters; pharmaceutical and wellness products encompassing medicated oils, capsules and topical analgesics; leisure services including theme parks operations such as the Tiger Balm Gardens; and property investments across Asia. The company operates mainly in Singapore, Malaysia, and other Southeast Asian markets. Founded in 1924 and headquartered in Singapore, Haw Par leverages its established brands and diversified portfolio to cater to both consumer healthcare and leisure segments. Recently, Haw Par Corporation has focused on digital transformation of its consumer products division and expanded its strategic partnerships with regional healthcare distributors to increase market penetration. It also intensified efforts in e-commerce platforms for its healthcare brands and launched new product variants to cater to evolving consumer preferences. Furthermore, the company has undertaken portfolio optimization by rationalizing non-core assets and investing selectively in high-growth segments within its leisure and healthcare businesses, aligning with its long-term growth strategy. Haw Par continues to explore strategic alliances and acquisition opportunities in Asia to enhance its market footprint and product offerings. The company operates through its subsidiaries and owns a portfolio of well-known healthcare brands with Tiger Balm as its flagship product. Haw Par's diversified business segments include consumer healthcare products, leisure, and property investment, targeting retail consumers, healthcare providers, and leisure visitors primarily in Southeast Asia but with expanding presence in adjacent regions. Its longstanding heritage and strong distribution network underpin its market leadership in the consumer medicated oil and ointment categories. In summary, Haw Par Corporation Limited is a leading Singaporean conglomerate specializing in healthcare consumer products, leisure, and property investments, with a history dating to 1924. It has recently undertaken strategic shifts emphasizing digital and regional expansion, product innovation, and portfolio streamlining to sustain growth and competitiveness in the Southeast Asian markets and beyond.